Alergologia Polska - Polish Journal of Allergology

Comparison of subcutaneous (SCIT) and sublingual (SLIT) immunotherapy in allergic rhinitis and allergic asthma

Adam Perek 1
,
Julia Raszewska 1
,
Wiktor Jabłoński 1
,
Klaudia Kapelka 2
,
Gabriel Mandera 1
,
Karolina Pyrtek 3
,
Julia Świerczek 4
,
Weronika Targosz 4
,
Dawid Sobański 5

  1. St. Barbara Provincial Specialist Hospital No. 5, Sosnowiec, Poland

  2. Blessed Virgin Mary Provincial Specialist Hospital, Czestochowa, Poland

  3. District Hospital, Zawiercie, Poland

  4. KKS Statistics, Poland

  5. Greater Poland Specialist Centre, Provincial Hospital, Poznan, Poland

Alergologia Polska – Polish Journal of Allergology

DOI: https://doi.org/10.5114/pja.2026.164983
Data publikacji online: 2026/09/25
Article file
PJA-Comparison.pdf
  1. Durham SR, Shamji MH. Allergen immunotherapy: past, present and future. Nat Rev Immunol 2022; 23: 317-28.
  2. Samoliński B, Raciborski F, Lipiec A, et al. Epidemiologia chorób alergicznych w Polsce (ECAP). Alergol Pol 2014; 1: 10-18.
  3. Respondek M, Prendergast C, Brożek B, Barański K. The prevalence of allergic rhinitis, atopic dermatitis and asthma in the population of children in Poland. Pediatr Pol 2026; 101: 68-72.
  4. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol 2011; 127 (1 Suppl): S1-55.
  5. Kowalski ML. Wskazania do immunoterapii alergenowej – algorytm kwalifikacji. Alergol Pol 2018; 5: 129-32.
  6. Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic review and meta-analysis. Allergy 2017; 72: 1597-631.
  7. Park M, Kapoor S, Yi J, Hura N, Lin SY. Sublingual immunotherapy persistence and adherence in real-world settings: a systematic review. Allergy Rhinol 2023; 13: 924-41.
  8. Kiel MA, Röder E, Gerth van Wijk R, et al. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol 2013; 132: 353-60.e2.
  9. Lemberg ML, Berk T, Shah-Hosseini K, et al. Sublingual versus subcutaneous immunotherapy: patient adherence at a large German allergy center. Patient Prefer Adherence 2017; 11: 63-70.
  10. Hardin FM, Eskander PN, Franzese C. Cost-effective analysis of subcutaneous vs sublingual immunotherapy from the payor’s perspective. OTO Open 2021; 5: 2473974X211052955.
  11. Bilancia M, Pasculli G, Di Bona D. A non-stationary Markov model for economic evaluations of grass pollen allergoid immunotherapy. PLoS One 2020; 15: e0232753.
  12. Reinhold T, Brüggenjürgen B. Cost-effectiveness of grass pollen SCIT compared with SLIT and symptomatic treatment. Allergo J Int 2017; 26: 7-15.
  13. Olsson P, Skröder C, Ahlbeck L, et al. HealthSWEDE: costs with sublingual immunotherapy – a Swedish questionnaire study. Allergy Asthma Clin Immunol 2021; 17: 55.
  14. Ellis AK, Gagnon R, Hammerby E, et al. Sublingual immunotherapy tablet for the treatment of house dust mite allergic rhinitis in Canada: an alternative to minimize treatment costs? Allergy Asthma Clin Immunol 2019; 15: 27.
  15. Nittner-Marszalska M. SLIT w alergiach układu oddechowego – status quo 2017. Adv Dermatol Allergol 2017; 34: 119-24.
  16. Gawlik R. Kliniczne przeciwwskazania do immunoterapii alergenowej – bezwzględne i względne oraz stałe i czasowe. Alergol Pol 2018; 5: 180-5.
  17. Tempels-Pavlica Ž, Aarts MCJ, Welsing PMJ, et al. House dust mite sublingual allergen immunotherapy tablet is safe and well tolerated in Dutch clinical practice. Front Allergy 2024; 5: 1355324.
  18. Jutel M, Gajdanowicz P. Mechanisms induced by allergen immunotherapy – state of knowledge in 2018. Alergol Pol 2018; 5: 175-9.
  19. Jutel M, Akdis CA. Immunological mechanisms of allergen-specific immunotherapy. Allergy 2011; 66: 725-32.
  20. Rapiejko A, Sosnowski TR, Sosnowski K, Jurkiewicz D. Experimental assessment of allergenic tree pollen deposition patterns in the paediatric nasal cavity model. Alergol Pol 2025; 12: 292-304.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
SUBMIT YOUR PAPER
Share
without publication fees
Coverage in
Integrated with
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications